



FACT SHEET (Links)

ABOUT

- [Why. How. What.](#)
- [mRNA Universal Coronavirus Vaccine \(UCV\) by NORVAX UK and mRNA UCV Consortium](#)
- [mRNA Vaccine Platform by Norsk Vaksinefabrikk](#)
- [mRNA UCV Consortium by NORVAX UK Ltd.](#)
- [NORVAX-LNP by Norvax AS with SINTEF](#)
- [Current Engagements](#)
- [Our Social Principles](#)
- [Code of Conduct – Norvax ethical framework](#)
- [About Governance. Euronext Growth Rules.](#)
- [About MY ECAM](#)
- [Team](#)

STRATEGIC TECHNOLOGY PARTNERS AND PREFERRED VENDORS

- | | |
|---|---------------------------------|
| • AmpTec/Merck | • IQVIA |
| • Cytiva | • Merck KGaA |
| • Emtunga/AFRY | • SINTEF |
| • eTheRNA | • Syntegon |
| • Imperial College London
Consultants | • Watson-Marlow |
| | • WSP |

PRESS

- [Norvax in the News in Norway](#)
- [PR: Maren Bækkelund Ellingsen WergelandApenes. mbe@wask.no +47 901 77 951](#)

ON SOCIAL MEDIA

- [Twitter](#) and [LinkedIn](#)

MEMBER OF

- [Legemiddelindustrien](#) and [Norsk Industri](#)

AUDITOR

- [PwC Norway](#)

LEGAL ADVISORS

- [Tenden Advokatfirma](#)

NORSK VAKSINEFABRIKK SUPPORTED BY

- [Innovation Norway](#)
- [The Research Council of Norway](#)

NORVAX COMPANY INFORMATION

- [Norvax UK Limited, 219 Kensington High Street, London, England, W8 6BD Company No. 12881085](#)
- [Norvax AS, Borgeskogen 65, 3160 Stokke, , Norway. Company No. 925 541 834](#)
- [Founder: Peter A. Jensen, MFA BSc \(Hons\), CEO & Chairman](#)
- [Contact: peter.jensen@ecambiomed.com](#)

WEBSITES

- [norvax.no](#)
- [norvax.uk](#)
- [mrnaucv.com](#)
- [vaxcomm.com](#)